Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Polygenic predisposition to breast cancer and the risk of coronary artery disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Association of the blood eosinophil count with end-organ symptoms

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical, Physiologic, and Behavioral Evaluation of Permanently Catheterized NMRI Mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The role of excess reactive oxygen species (ROS) with consequent DNA/RNA damage is now recognized as a hallmark of cancer. In JAK2V617F mutated myeloproliferative neoplasms, ROS have been suggested to be important factors in disease initiation and progression. Ruxolitinib is the most widely used drug for myelofibrosis, because it improves symptom-score. However, both the anti-clonal potential and improvement in overall survival are limited. We investigated the impact of ruxolitinib on formation of superoxide radical and hydrogen peroxide by monocytes in sequentially acquired blood samples from patients with myelofibrosis. We also investigated the impact on RNA and DNA damage by measuring urinary excretion of 8-oxo-Guo and 8-oxo-d-Guo. The formation of superoxide by monocytes was reduced significantly during ruxolitinib therapy, but no impact on the formation of hydrogen peroxide by monocytes or the systemic amount of oxidatively damaged RNA or DNA could be demonstrated. We conclude that ruxolitinib holds little anti-oxidative potential.

Original languageEnglish
JournalLeukemia and Lymphoma
Pages (from-to)1-9
Number of pages9
ISSN1042-8194
DOIs
Publication statusE-pub ahead of print - 20 Feb 2019

ID: 56643066